1. Home
  2. XLO vs CASI Comparison

XLO vs CASI Comparison

Compare XLO & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XLO
  • CASI
  • Stock Information
  • Founded
  • XLO 2016
  • CASI 1991
  • Country
  • XLO United States
  • CASI China
  • Employees
  • XLO N/A
  • CASI N/A
  • Industry
  • XLO Biotechnology: Pharmaceutical Preparations
  • CASI Biotechnology: Pharmaceutical Preparations
  • Sector
  • XLO Health Care
  • CASI Health Care
  • Exchange
  • XLO Nasdaq
  • CASI Nasdaq
  • Market Cap
  • XLO 35.7M
  • CASI 35.8M
  • IPO Year
  • XLO 2021
  • CASI 1996
  • Fundamental
  • Price
  • XLO $0.81
  • CASI $1.92
  • Analyst Decision
  • XLO Buy
  • CASI Strong Buy
  • Analyst Count
  • XLO 2
  • CASI 1
  • Target Price
  • XLO $3.00
  • CASI $4.00
  • AVG Volume (30 Days)
  • XLO 453.9K
  • CASI 305.0K
  • Earning Date
  • XLO 11-06-2025
  • CASI 11-13-2025
  • Dividend Yield
  • XLO N/A
  • CASI N/A
  • EPS Growth
  • XLO N/A
  • CASI N/A
  • EPS
  • XLO N/A
  • CASI N/A
  • Revenue
  • XLO $15,001,000.00
  • CASI $31,564,000.00
  • Revenue This Year
  • XLO $519.70
  • CASI N/A
  • Revenue Next Year
  • XLO $44.57
  • CASI N/A
  • P/E Ratio
  • XLO N/A
  • CASI N/A
  • Revenue Growth
  • XLO 536.45
  • CASI 36.64
  • 52 Week Low
  • XLO $0.62
  • CASI $1.09
  • 52 Week High
  • XLO $1.70
  • CASI $7.50
  • Technical
  • Relative Strength Index (RSI)
  • XLO 62.62
  • CASI 51.04
  • Support Level
  • XLO $0.79
  • CASI $1.77
  • Resistance Level
  • XLO $0.91
  • CASI $2.08
  • Average True Range (ATR)
  • XLO 0.04
  • CASI 0.20
  • MACD
  • XLO 0.00
  • CASI 0.02
  • Stochastic Oscillator
  • XLO 50.46
  • CASI 71.84

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Share on Social Networks: